(UroToday.com) The European Society of Medical Oncology (ESMO) 2021 annual meeting’s prostate cancer session included a presentation by Dr. Stephen Freedland discussing treatment patterns and overall survival among men with metastatic castration-sensitive prostate cancer (mCSPC). Indeed, androgen deprivation therapy (ADT) remains the backbone of therapy for mCSPC. While earlier studies (pre-2012) adding first-generation nonsteroidal antiandrogens to ADT failed to show consistent OS improvement, clinical trials since 2014 combining docetaxel or novel hormonal therapies to ADT have shown improved OS over ADT alone in this population, with even greater benefit seen than in metastatic castration-resistant prostate cancer (mCRPC) population.

X